Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05276830 · ClinicalTrials.gov registry record · Phase 2
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
A Phase 2 study, sponsored by BioXcel Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT05276830 is a Phase 2 study that was terminated before completion, run by BioXcel Therapeutics. The registered enrollment target is 5 participants.
The verdict
NCT05276830, a Phase 2 study, was terminated before completion, sponsored by BioXcel Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled parallel group 3-arm study assessing efficacy, safety, and tolerability of two doses BXCL501 in male and female geriatric residents (65 years and older) with acute agitation associated with all forms of dementia (i.e., probably Alzheimer's Disease, vascular dementia; mixed; frontotemporal dementia) excluding Parkinson's-Related Dementia and Lewy Body Dementia.
Interventions
- DRUG Placebo film
- DRUG BXCL501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2022-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05276830
The ClinicalTrials.gov registry entry for NCT05276830 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioXcel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo film is the first listed.
NCT05276830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05276830 about?
NCT05276830 is a clinical study titled "An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia". A randomized, double-blind, placebo-controlled parallel group 3-arm study assessing efficacy, safety, and tolerability of two doses BXCL501 in male and female geriatric residents (65 years and older) with acute agitation associated with all forms of dementia (i.e., probably Alzheimer's Disease, vasc...
What is the current status of trial NCT05276830?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2022-02-08. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT05276830?
The interventions under investigation include: Placebo film (DRUG), BXCL501 (DRUG).
Who is sponsoring clinical trial NCT05276830?
This trial is sponsored by BioXcel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.